BRPI0512893A - métodos de determinação da eficácia da terapia no tratamento da amiloidose e de identificação de paciente como prodrÈmico para doença associada com a deposição amilóide e respectivos compostos - Google Patents
métodos de determinação da eficácia da terapia no tratamento da amiloidose e de identificação de paciente como prodrÈmico para doença associada com a deposição amilóide e respectivos compostosInfo
- Publication number
- BRPI0512893A BRPI0512893A BRPI0512893-5A BRPI0512893A BRPI0512893A BR PI0512893 A BRPI0512893 A BR PI0512893A BR PI0512893 A BRPI0512893 A BR PI0512893A BR PI0512893 A BRPI0512893 A BR PI0512893A
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- treatment
- amyloidosis
- therapy
- determining
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Radiology & Medical Imaging (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Métodos de determinação da eficácia da terapia no tratamento da amiloidose e de identificação de paciente como prodrómico para doença associada com a deposição amilóide e respectivos compostos O presente método para determinar a eficácia da terapia no tratamento da amiloidose envolve administrar ao paciente dele necessitado um composto da fórmula (I) ou Fórmula (II) ou estruturas 1-45 e capturar as imagens do paciente. Depois de capturar as referidas imagens, pelo menos um agente anti-amilóide é administrado ao citado paciente. Depois, uma quantidade efetiva de um composto da fórmula (I) ou Fórmula (II) ou estruturas 1-45 é administrada ao paciente e o paciente tem novamente as imagens capturadas. Finalmente, os níveis da linha de base da deposição de amilóide no paciente antes do tratamento com o agente anti-amilóide são comparados com os níveis de deposição de amilóide no paciente a seguir ao tratamento com o agente anti-amilóide.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58448704P | 2004-07-02 | 2004-07-02 | |
| US60/584,487 | 2004-07-02 | ||
| PCT/US2005/023617 WO2006014381A2 (en) | 2004-07-02 | 2005-07-01 | Use of thioflavin radiolabeled derivatives in amyloid imaging gor assessing anti-amyloid therapies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0512893A true BRPI0512893A (pt) | 2008-04-15 |
| BRPI0512893B1 BRPI0512893B1 (pt) | 2019-12-24 |
| BRPI0512893B8 BRPI0512893B8 (pt) | 2021-07-27 |
Family
ID=35504952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512893A BRPI0512893B8 (pt) | 2004-07-02 | 2005-07-01 | métodos de determinação da eficácia da terapia no tratamento da amiloidose e de identificação de paciente como prodrômico para doença associada com a deposição amilóide e respectivos compostos |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8147798B2 (pt) |
| EP (1) | EP1771208B1 (pt) |
| JP (1) | JP2008505115A (pt) |
| CN (2) | CN101137397A (pt) |
| AU (1) | AU2005270026A1 (pt) |
| BR (1) | BRPI0512893B8 (pt) |
| CA (2) | CA2587248C (pt) |
| CY (1) | CY1114644T1 (pt) |
| DK (1) | DK1771208T3 (pt) |
| ES (1) | ES2427963T3 (pt) |
| NO (1) | NO339187B1 (pt) |
| PL (1) | PL1771208T3 (pt) |
| PT (1) | PT1771208E (pt) |
| RU (1) | RU2007104107A (pt) |
| SI (1) | SI1771208T1 (pt) |
| WO (1) | WO2006014381A2 (pt) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7270800B2 (en) * | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| RU2324686C2 (ru) * | 2000-08-24 | 2008-05-20 | Юнивесити Оф Питсбэг | ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| NZ567324A (en) * | 2003-02-01 | 2009-08-28 | Wyeth Corp | Active immunization to generate antibodies to soluble A-beta |
| US8236282B2 (en) * | 2003-08-22 | 2012-08-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Benzothiazole derivative compounds, compositions and uses |
| EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| GB0516564D0 (en) * | 2005-08-12 | 2005-09-21 | Ge Healthcare Ltd | Fluorination process |
| CN101355940B (zh) * | 2005-09-16 | 2013-03-27 | 匹兹堡大学高等教育联邦体系 | 用于检测具有至少一种促淀粉样变蛋白的淀粉样沉积物的体内或体外方法 |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| WO2008118122A2 (en) | 2006-05-08 | 2008-10-02 | Molecular Neuroimaging, Llc | Compounds and amyloid probes thereof for therapeutic and imaging uses |
| TW200813035A (en) | 2006-06-19 | 2008-03-16 | Astrazeneca Ab | Novel heteroaryl substituted benzoxazoles |
| CN101293878B (zh) * | 2007-04-25 | 2010-12-15 | 中国科学院上海应用物理研究所 | 苯并噻唑苯胺类化合物及其制备方法和应用 |
| DK2182983T3 (da) * | 2007-07-27 | 2014-07-14 | Janssen Alzheimer Immunotherap | Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer |
| RU2475267C2 (ru) * | 2007-08-30 | 2013-02-20 | Джи-И Хелткер Лимитед | Радиофармацевтическая композиция |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| JP5603855B2 (ja) | 2008-04-04 | 2014-10-08 | アビッド レディオファーマシューティカルズ、インク． | 神経変成疾患の放射性薬剤による画像化 |
| CA2737028C (en) * | 2008-09-23 | 2017-06-27 | Wista Laboratories Ltd. | Ligands for aggregated tau molecules |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| EP2365974B1 (en) * | 2008-11-06 | 2013-12-25 | SNU R&DB Foundation | Fluorinated benzothiazole derivatives, preparation method thereof and imaging agent for diagnosing altzheimer's disease using the same |
| US20130084245A1 (en) * | 2010-02-25 | 2013-04-04 | Wyeth Llc | Pet monitoring of a-beta-directed immunotherapy |
| WO2014004664A2 (en) * | 2012-06-27 | 2014-01-03 | Mayo Foundation For Medical Education And Research | Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives |
| US9422286B2 (en) | 2014-01-27 | 2016-08-23 | Washington University | Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease |
| CA2994178C (en) | 2015-08-18 | 2024-03-19 | The Regents Of The University Of California | Nitroxide containing amyloid binding agents for imaging and therapeutic uses |
| BR112018068066B1 (pt) * | 2016-03-11 | 2023-11-28 | Ac Immune Sa | Compostos bicíclicos e seu uso, composição diagnóstica e farmacêutica, misturas, métodos de coleção de dados para diagnóstico, para determinar uma predisposição a, para monitorar transtorno residual e para prever a capacidade de resposta de um paciente sofrendo de transtorno ou anormalidade associado com agregados de alfa-sinucleína, métodos para determinar a quantidade de agregados de alfa-sinucleína e para preparar um composto, kit teste e kit para preparar uma preparação radio farmacêutica |
| US20230158178A1 (en) * | 2020-03-16 | 2023-05-25 | Emory University | Radionuclide Tracers of 1-Amino-3,4-Difluorocyclopentane-1-Carboxylic Acid, Derivatives, and Uses Thereof |
| CN116953008B (zh) * | 2023-06-14 | 2024-10-22 | 汕头大学医学院第二附属医院 | 基于磁共振成像的β淀粉样蛋白浓度检测方法及系统 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030092003A1 (en) * | 1999-12-29 | 2003-05-15 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of Alzheimer's disease |
| RU2324686C2 (ru) * | 2000-08-24 | 2008-05-20 | Юнивесити Оф Питсбэг | ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА |
| US7270800B2 (en) * | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| CA2444214A1 (en) * | 2001-04-23 | 2002-10-31 | The Trustees Of The University Of Pennsylvania | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
| GB0130305D0 (en) * | 2001-12-19 | 2002-02-06 | Amersham Plc | Compounds for imaging alzheimers disease |
| AU2003212490A1 (en) | 2002-02-13 | 2003-09-04 | Amersham Plc | Benzothiazole derivatives for in vivo imaging of amyloid plaques |
| CA2438032C (en) * | 2003-03-14 | 2013-05-07 | University Of Pittsburgh | Benzothiazole derivative compounds, compositions and uses |
| GB0307855D0 (en) | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
| JP2008505116A (ja) * | 2004-07-02 | 2008-02-21 | ユニバーシティー オブ ピッツバーグ | アミロイド沈着を伴う疾患の前駆形態の診断方法 |
-
2005
- 2005-07-01 AU AU2005270026A patent/AU2005270026A1/en not_active Abandoned
- 2005-07-01 JP JP2007519500A patent/JP2008505115A/ja active Pending
- 2005-07-01 CA CA2587248A patent/CA2587248C/en not_active Expired - Lifetime
- 2005-07-01 PL PL05787557T patent/PL1771208T3/pl unknown
- 2005-07-01 CN CNA2005800263010A patent/CN101137397A/zh active Pending
- 2005-07-01 RU RU2007104107/04A patent/RU2007104107A/ru not_active Application Discontinuation
- 2005-07-01 SI SI200531765T patent/SI1771208T1/sl unknown
- 2005-07-01 ES ES05787557T patent/ES2427963T3/es not_active Expired - Lifetime
- 2005-07-01 WO PCT/US2005/023617 patent/WO2006014381A2/en not_active Ceased
- 2005-07-01 CN CN2012104014697A patent/CN102973954A/zh active Pending
- 2005-07-01 US US11/666,083 patent/US8147798B2/en active Active
- 2005-07-01 EP EP05787557.7A patent/EP1771208B1/en not_active Expired - Lifetime
- 2005-07-01 BR BRPI0512893A patent/BRPI0512893B8/pt active IP Right Grant
- 2005-07-01 DK DK05787557.7T patent/DK1771208T3/da active
- 2005-07-01 CA CA2830939A patent/CA2830939C/en not_active Expired - Lifetime
- 2005-07-01 PT PT57875577T patent/PT1771208E/pt unknown
-
2007
- 2007-01-31 NO NO20070593A patent/NO339187B1/no unknown
-
2012
- 2012-03-06 US US13/412,823 patent/US8343457B2/en not_active Expired - Lifetime
- 2012-10-23 US US13/658,483 patent/US8580229B2/en not_active Expired - Lifetime
-
2013
- 2013-09-10 CY CY20131100776T patent/CY1114644T1/el unknown
- 2013-10-09 US US14/050,018 patent/US20140105820A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2427963T3 (es) | 2013-11-05 |
| BRPI0512893B1 (pt) | 2019-12-24 |
| AU2005270026A1 (en) | 2006-02-09 |
| US20080219931A1 (en) | 2008-09-11 |
| SI1771208T1 (sl) | 2013-10-30 |
| NO20070593L (no) | 2007-03-27 |
| CN101137397A (zh) | 2008-03-05 |
| US8343457B2 (en) | 2013-01-01 |
| US20120177572A1 (en) | 2012-07-12 |
| US8147798B2 (en) | 2012-04-03 |
| WO2006014381A3 (en) | 2007-01-18 |
| WO2006014381A2 (en) | 2006-02-09 |
| CA2830939A1 (en) | 2006-02-09 |
| CA2587248A1 (en) | 2006-02-09 |
| US8580229B2 (en) | 2013-11-12 |
| NO339187B1 (no) | 2016-11-14 |
| WO2006014381A9 (en) | 2006-04-13 |
| EP1771208B1 (en) | 2013-06-19 |
| CA2830939C (en) | 2017-02-28 |
| DK1771208T3 (da) | 2013-09-02 |
| EP1771208A2 (en) | 2007-04-11 |
| JP2008505115A (ja) | 2008-02-21 |
| PT1771208E (pt) | 2013-09-24 |
| US20130045164A1 (en) | 2013-02-21 |
| CY1114644T1 (el) | 2016-10-05 |
| CN102973954A (zh) | 2013-03-20 |
| CA2587248C (en) | 2014-01-07 |
| BRPI0512893B8 (pt) | 2021-07-27 |
| US20140105820A1 (en) | 2014-04-17 |
| RU2007104107A (ru) | 2008-08-10 |
| PL1771208T3 (pl) | 2013-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0512893A (pt) | métodos de determinação da eficácia da terapia no tratamento da amiloidose e de identificação de paciente como prodrÈmico para doença associada com a deposição amilóide e respectivos compostos | |
| RU2012124268A (ru) | Бензимидазольные соединения и их применения | |
| RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
| JP2006501240A5 (pt) | ||
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| EA200870254A1 (ru) | Способ лечения воспалительных заболеваний | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| JP2019509318A5 (pt) | ||
| JP2019517587A5 (pt) | ||
| DE602007011913D1 (de) | Pharmazeutische kombination mit 3- (3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol | |
| JP2009544585A5 (pt) | ||
| ATE470151T1 (de) | Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| ES2385138T3 (es) | Modelo de roedor de enfermedad para dolor muscular crónico | |
| MX2020001342A (es) | Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas. | |
| EA201300314A1 (ru) | Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство | |
| RU2005135428A (ru) | Поглощение макромолекул | |
| BR112012020185A2 (pt) | uso de preparações de heparina oral para tratar doenças e afecções do trato urinário. | |
| WO2012044783A3 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| MX2021015467A (es) | Compuestos y metodos de uso. | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| RU2010146309A (ru) | Фармацевтическая композиция для лечения фибромиалгии | |
| RU2016103098A (ru) | Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii | |
| BR0207786A (pt) | Uso de pimenta racemosa, bem como composição farmacêutica compreendendo um extrato do referido composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: COMPLEMENTAR TAXA DE EXPEDICAO DA CARTA PATENTE REFERENTE PETICAO NO 800160229695 DE 15/08/2016. |
|
| B15G | Petition not considered as such [chapter 15.7 patent gazette] | ||
| B12F | Other appeals [chapter 12.6 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/12/2019, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B25D | Requested change of name of applicant approved |
Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/07/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |